A privately held biopharmaceutical company focused on the creation and clinical development of a pipeline of disease-modifying small molecule drug candidates that stop neurological disease processes and restore and preserve the synapse, the building blocks of brain health and function. Cognition’s lead candidate, Elayta™, is a proprietary first-in-class, orally dosed and highly brain penetrant small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. A novel approach to synaptic protection and restoration in Alzheimer’s disease.
